VESALIUS-CV Mortality Signal Breaks PCSK9 Inhibitor Evidence Ceiling — But Absolute Data and HTA Gaps Remain

Repatha Reduces Death Risk in High-Risk Primary Prevention Patients

Amgen announced new findings from a pre-specified analysis of the Phase 3 VESALIUS-CV trial, showing that Repatha (evolocumab) reduced the risk of death by 20% in over 12,000 high-risk adults without a prior heart attack or stroke, when added to statins or other LDL-C-lowering treatments. The reduction in overall and cardiovascular deaths began after approximately 1.5 years and continued through a median follow-up of 4.6 years. These results, presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in Circulation, highlight Repatha's potential to extend life by preventing major cardiovascular events and underscore the importance of early, aggressive LDL-C lowering.

• The pre-specified analysis of the VESALIUS-CV trial demonstrated that Repatha significantly reduced the risk of death by 20% in high-risk patients without a prior heart attack or stroke. This reduction encompassed both overall deaths and cardiovascular deaths, with benefits becoming apparent after about 1.5 years of treatment and sustained over a median follow-up of 4.6 years. This finding is particularly impactful as it positions Repatha as the first and only PCSK9 inhibitor to show a reduction in all-cause mortality in this primary prevention population.
• Beyond mortality, additional analyses from VESALIUS-CV showed Repatha's efficacy in reducing the risk of first, subsequent, and total cardiovascular events. The reduction in heart attacks was observed as early as six months, primarily driven by a decrease in type 1 myocardial infarctions and larger infarctions. These consistent benefits across patient subgroups reinforce the drug's broad protective effect against the progression of cardiovascular disease, altering patient trajectories by preventing recurrent events.
• Amgen also presented real-world studies highlighting significant disparities in lipid management. One study revealed that patients with coronary artery disease but no prior heart attack or stroke were often undertreated and failed to achieve recommended LDL-C levels due to low rates of treatment initiation and intensification. Another study showed women at high risk were less likely than men to receive intensive lipid-lowering treatment and reach LDL-C goals, emphasizing an urgent need for more timely and aggressive LDL-C lowering strategies.

Repatha's Landmark Mortality Reduction in VESALIUS-CV

Two studies from the provided literature address high-risk adults without prior myocardial infarction or stroke in a primary prevention context.

The JUPITER trial evaluated rosuvastatin 20 mg versus placebo in 17,802 apparently healthy men and women with low-density lipoprotein cholesterol <130 mg/dL and high-sensitivity C-reactive protein ≥2 mg/L. For the composite endpoint of myocardial infarction, stroke, revascularization, or death, the 5-year number needed to treat (NNT) was 20 (95% CI, 14 to 34). For the restricted "hard" endpoint of myocardial infarction, stroke, or death, the 5-year NNT was 29 (95% CI, 19 to 56). Subgroup analyses demonstrated 5-year NNT values below 50 across all examined subgroups, including values of 17 for men and 31 for women, and 14 for those with estimated Framingham risks greater than 10%.

A systematic review and meta-analysis examining low-dose aspirin for primary prevention of cardiovascular disease — encompassing 10 randomized clinical trials through August 2021 — reported that aspirin was associated with a significant reduction in the risk of major adverse cardiovascular events (MACE) (RR 0.89, 95% CI 0.84–0.93), myocardial infarction (RR 0.86, 95% CI 0.78–0.95), and ischemic stroke (RR 0.84, 95% CI 0.76–0.93). However, aspirin also increased the risk of major bleeding (RR 1.42, 95% CI 1.26–1.60), intracranial hemorrhage (RR 1.33, 95% CI 1.11–1.59), and gastrointestinal bleeding (RR 1.91, 95% CI 1.44–2.54). A post hoc subgroup analysis indicated a significant rate reduction in patients aged ≤70 years but not in patients aged >70 years, and a trend toward net benefit was observed in the high cardiovascular risk subgroup, with a number needed to treat for MACE of 682 versus 2,191 in the low-risk subgroup.

Unpacking the VESALIUS-CV Trial Design and Broader Efficacy

The trials represented in the available literature address cardiovascular outcomes across several high-risk populations, though none of the retrieved studies specifically corresponds to the VESALIUS-CV trial or focuses exclusively on high-risk adults without prior myocardial infarction or stroke as a defined enrollment criterion. The studies below represent the closest available evidence on trial design parameters and endpoints for cardiovascular risk reduction in high-risk adult populations.

The knowledge base does not have sufficient information on this aspect.

Addressing Unmet Needs in Primary CV Prevention with Repatha

Managing cardiovascular risk in high-risk adults who have not yet experienced a myocardial infarction or stroke presents a complex set of clinical and strategic challenges. Risk stratification, treatment tolerability, and the persistence of residual risk despite guideline-directed therapy collectively limit the effectiveness of current primary prevention approaches.

• Risk stratification discordance across tools: Different cardiovascular risk assessment tools yield substantially divergent classifications for the same patient population. In a study of 1,425 people living with HIV, agreement rates between ASCVD and other tools were 82% for Framingham heart study risk score, 94% for modified FRS, 91% for DAD, and only 36% for SCORE2 for high-risk countries. SCORE2 identified 71.7% of patients at high- to very high-risk, compared with 42.8% classified as higher risk by ASCVD (10-year risk above 7.5%). This variability directly affects eligibility determinations: 75.3% of patients would qualify for lipid-lowering agents under 2021 European guidelines versus 47.1% under 2019 American Cardiology guidelines.

• Underutilisation of lipid-lowering therapy and suboptimal LDL-C targeting: Despite well-defined risk-adapted treatment targets from the European Society of Cardiology, these targets "are not sufficiently achieved in the clinical routine." The implementation of cardiovascular prevention through lipid-lowering therapy was described as "far from desired levels" in high-risk cohorts. Additionally, LDL-C, non-HDL-C, and triglycerides demonstrate high variability in their relationship to apolipoprotein B (apoB) — apoB ranges necessary to capture 95% of all observations at pre-specified LDL-C levels of 130 mg/dL spanned 85.8–108.8 mg/dL — meaning standard lipid panels may not adequately capture true atherogenic burden.

• Residual inflammatory risk persisting beyond lipid lowering: Even with more intensive lipid-lowering therapy (statins, PCSK9 inhibitors, ezetimibe), meta-analysis of 14 randomised controlled trials including 133,109 patients demonstrated no significant difference in hsCRP levels between more intensive and less intensive therapy (mean difference, -0.02; CI, -0.06, 0.02; P = 0.31). A residual inflammatory risk persists despite contemporary lipid-lowering agents, with a statistically significant absolute risk reduction in all-cause mortality of only 0.5% observed in patients with higher baseline hsCRP (RD, -0.005; CI, -0.009, -0.001; P = 0.01).

• Statin intolerance limiting long-term adherence: Statin-associated muscle symptoms (SAMS) represent "a major barrier to maintain long-term persistence to statin treatment," occurring in up to approximately one-third of patients in clinical practice. SAMS reduce quality of life, and rare complications may extend to rhabdomyolysis. While re-exposure to very low doses with slow uptitration allows the "vast majority of patients" to continue statin therapy long term, those who cannot reach LDL targets at their maximally tolerated dose require combination therapy with ezetimibe and PCSK9 inhibitors.

• Antiplatelet therapy: balancing efficacy against bleeding risk in primary prevention: In patients with diabetes but no prior cardiovascular disease, aspirin at 100 mg daily reduced serious vascular events (8.5% vs. 9.6%; rate ratio, 0.88; 95% CI, 0.79 to 0.97; P=0.01) but increased major bleeding events (4.1% vs. 3.2%; rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), with "the absolute benefits largely counterbalanced by the bleeding hazard." Clopidogrel showed no significant difference compared with aspirin in net adverse clinical events (HR: 0.97; 95% CI: 0.79–1.19) in a matched cohort of high-risk diabetic patients, though a trend toward lower GI bleeding was observed (HR: 0.48; 95% CI: 0.23–1.01).

Repatha's Mortality Benefit Reshapes Primary CV Prevention

The latest findings from the VESALIUS-CV trial represent a pivotal moment in cardiovascular disease prevention, extending the proven benefits of evolocumab beyond patients with established atherosclerotic cardiovascular disease (ASCVD) into the realm of primary prevention. For the first time, a PCSK9 inhibitor has demonstrated a significant 20% reduction in the risk of death in high-risk adults who have not yet experienced a heart attack or stroke. This is not merely about preventing a first event; it's about extending life, a profound outcome that resonates deeply with patients and clinicians alike.

This evidence strongly reinforces the 'lower is better' paradigm for LDL-C, suggesting that aggressive and sustained lipid lowering, even to very low levels, is critical for optimal long-term cardiovascular health. Previous long-term studies have already shown that achieving LDL-C levels down to <20 mg/dL is associated with a lower risk of cardiovascular outcomes without significant safety concerns. The VESALIUS-CV data now underscore the importance of initiating such intensive lowering earlier in the disease continuum.

For healthcare systems and prescribers, this presents both an opportunity and a challenge. While the mortality benefit is compelling, considerations around cost-effectiveness and patient access will remain paramount. Ensuring that this life-extending therapy reaches the high-risk individuals who stand to benefit most will require careful navigation of reimbursement policies and patient support programs. Furthermore, maintaining long-term adherence to an injectable therapy in an asymptomatic population will be a key factor in realizing these benefits in the real world. As the landscape of lipid-lowering therapies continues to evolve, the sustained differentiation of evolocumab, particularly with this robust mortality data, will be crucial for its continued impact.